11 research outputs found

    Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion

    No full text
    <div><p>The CA125 antigen is found in the serum of many patients with serous ovarian cancer and has been widely used as a disease marker. CA125 has been shown to be an independent factor for clinical outcome in this disease. In The Cancer Genome Atlas ovarian cancer project, MUC16 expression levels are frequently increased, and the highest levels of MUC16 expression are linked to a significantly worse survival. To examine the biologic effect of the proximal portion of MUC16/CA125, NIH/3T3 (3T3) fibroblast cell lines were stably transfected with the carboxy elements of MUC16. As few as 114 amino acids from the carboxy-terminal portion of MUC16 were sufficient to increase soft agar growth, promote matrigel invasion, and increase the rate of tumor growth in athymic nude mice. Transformation with carboxy elements of MUC16 was associated with activation of the AKT and ERK pathways. MUC16 transformation was associated with up-regulation of a number of metastases and invasion gene transcripts, including IL-1Ī², MMP2, and MMP9. All observed oncogenic changes were exclusively dependent on the extracellular ā€œectodomainā€ of MUC16. The biologic impact of MUC16 was also explored through the creation of a transgenic mouse model expressing 354 amino acids of the carboxy-terminal portion of MUC16 (MUC16<sup>c354</sup>). Under a CMV, early enhancer plus chicken Ī² actin promoter (CAG) MUC16<sup>c354</sup> was well expressed in many organs, including the brain, colon, heart, kidney, liver, lung, ovary, and spleen. MUC16<sup>c354</sup> transgenic animals appear to be viable, fertile, and have a normal lifespan. However, when crossed with p53-deficient mice, the MUC16<sup>c354</sup>:p53<sup>+/-</sup> progeny displayed a higher frequency of spontaneous tumor development compared to p53<sup>+/-</sup> mice alone. We conclude that the carboxy-terminal portion of the MUC16/CA125 protein is oncogenic in NIH/3T3 cells, increases invasive tumor properties, activates the AKT and ERK pathways, and contributes to the biologic properties of ovarian cancer.</p></div

    MUC16<sup>c354</sup> transgenic mice.

    No full text
    <p>A) Strategy for MUC16<sup>c354</sup> conditional construct. A CMV early enhancer plus the chicken Ī² actin promoter (CAG) was used to drive the transcription of hrGFP between two loxPs and the downstream MUC16<sup>c354</sup> sequence. B) Southern blot shows 12 candidates of MUC16<sup>c354</sup> positive founders among 99 animals after the microinjection procedure. C) Western blot with anti-MUC16<sup>c114</sup> 4H11 was used to identify founders 9 (~50 copies) and 36 (~10 copies) for MUC16<sup>c354</sup> mouse colony development. A5 is a positive control from a stable transfected SKOV3 with MUC16<sup>c354</sup>. D) Histological analyses of tumors from double MUC16<sup>c354</sup>:p53<sup>+/-</sup> transgenic mice. Multiple sarcomas and lymphomas were identified in the double MUC16<sup>c354</sup>:p53<sup>+/-</sup> transgenic mice. Sections were stained with hematoxylin and eosin (H&E). Tumors included histocytic sarcoma in the uterus (I, Scale bar:100Ī¼m), liver (II, Scale bar:50Ī¼m), ovary (III, Scale bar:50Ī¼m) and bone marrow (IV, Scale bar:50Ī¼m); lymphoma in the ovary (V, Scale bar:50Ī¼m), kidney (VI, Scale bar:50Ī¼m), and lung (VII, Scale bar:50Ī¼m); and carcinoma in the lung (VIII, Scale bar:50Ī¼m). E) Transgenic mouse cancer-specific Kaplan-Meier survival curves: the MUC16<sup>c354</sup> mice (black line) showed no spontaneous tumor development over the first 18 months, similar to the wild type (WT, red dashed line). However, when MUC16<sup>c354</sup> mice were crossed with p53<sup>+/-</sup> mice, the double transgenic MUC16<sup>c354</sup>:p53<sup>+/-</sup> mice (green dashed line) showed a significantly worse overall survival due to spontaneous tumor development compared to either the p53<sup>+/-</sup> mice (red line) (p<0.014) or the MUC16<sup>c354</sup> mice. The number of tumors were p53<sup>+/-</sup> mice 20/107; MUC16c354 and p53<sup>+/-</sup> Mice 34/91; MUC16c354 1/72; and wild type 0/91.</p

    Effect of N-glycosylation on MUC16 transformation.

    No full text
    <p>A) Matrigel invasion assay for 3T3 transfected cell lines, phrGFP control vector or MUC16<sup>c114</sup> or MUC16<sup>3(Nā€”A)c114</sup> and MUC16<sup>c114</sup> treated with 0.1 Ī¼g/mL Tunicamycin. As seen earlier, MUC16<sup>c114</sup> cell lines were significantly different (p<0.0001) than the phrGFP vector control. The MUC16<sup>3(Nā€”A)c114</sup> cell line was still significantly more invasive (** p = 0.007) compared to the phrGFP vector control. Treatment with the N-glycosylation inhibitor Tunicamycin significantly inhibited matrigel invasion compared to the untreated MUC16<sup>c114</sup> (##p = 0.0003), and MUC16<sup>3(Nā€”A)c114</sup> is highly significant (### = p<0.0001) compared to MUC16<sup>c114</sup>, suggesting that N-glycosylation is critical for MUC16-induced matrigel invasion. B) Matrigel invasion assay for 3T3 transfected cell lines compared to the phrGFP control vector. 3T3 cells transfected with MUC16<sup>c114</sup> were treated with media alone, with 5 Ī¼g/mL of control pFUSE hIgG1-Fc2 fusion protein, with 5 Ī¼g/mL of MUC16<sup>c57-114</sup>-pFUSE hIgG1-Fc2 fusion protein, or with 5 Ī¼g/mL of <sup>117-244</sup>LGALS3-pFUSE hIgG1-Fc2 fusion protein, as detailed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0126633#pone.0126633.s006" target="_blank">S4 Fig</a> As seen earlier, the MUC16<sup>c114</sup> cell line was much more invasive than the phrGFP vector control 3T3 cells (p<0.0001), and this increase in invasion was unaffected by exposure to pFUSE vector only protein. In contrast, MUC16<sup>c114</sup> cell line treated with MUC16<sup>c57-114</sup>-pFUSE hIgG1-Fc2 fusion protein or <sup>117-244</sup>LGALS3-pFUSE hIgG1-Fc2 fusion protein demonstrated significant (# p = 0.0001) inhibition of matrigel invasion compared to MUC16<sup>c114</sup> control cells. C) Effect of MUC16 expression on ERK/AKT signaling. Phosphorylation of ERK1/2 (pT202/Y204) and AKT (S473) was increased in the 3T3 transfected with MUC16<sup>c114</sup>; however, the effect was much diminished in 3T3 cells transfected with the MUC16<sup>3(Nā€”A)c114</sup> vector. Despite the three asparagineā€”> alanine mutations, Western blot with the anti-MUC16 antibody, 4H11 mAb, showed a higher signal than either the phrGFP vector control or the native MUC16<sup>c114</sup> transfected cells, indicating that the high levels of MUC16<sup>3(Nā€”A)c114</sup> protein is expressed in the transfected 3T3 cells, and surface expression was confirmed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0126633#pone.0126633.s004" target="_blank">S2 Fig</a> Ī²-Actin normalized densitometry quantification values are shown below each Western blot in the figure. D) MUC16-positive tumor growth in athymic nude mice. Two million tumor cells were introduced into the flank of 20 nu/nu mice, and the mice were observed for tumor formation. Tumors were measured by calipers twice weekly. The differences in mean tumor volume were significantly greater for mice bearing MUC16<sup>c114</sup> tumors (p<0.0001). As seen earlier, 3T3 MUC16<sup>c114</sup> transfectant was highly significant at *** p<0.0001 compared to the phrGFP control vector. However, MUC16<sup>3(Nā€”A)c114</sup>3T3 transfectants did not show any significance over phrGFP vector control 3T3 cells, indicating that the mutations of N-glycosylation dramatically decreased <i>in vivo</i> tumor growth and invasion.</p

    Effects of truncated MUC16<sup>c114</sup> variants.

    No full text
    <p>A) Soft agar growth. 3T3 transfectants expressing either internal or external domain portions of MUC16<sup>c114</sup> (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0126633#pone.0126633.s003" target="_blank">S1 Fig</a>) were layered on soft agar, as described in the Material and Methods section. Colonies were counted and plotted. The data shown represent one of three experiments. Soft agar growth rates for MUC16<sup>c80</sup> and MUC16<sup>c86</sup> were significant (# p = 0.0111 and ## p = 0.0258, respectively) compared to MUC16<sup>c114</sup>, whereas a higher level of significance (###p<0.0001) was seen with MUC16<sup>c80</sup> transfectant compared to MUC16<sup>c86</sup>. B) Matrigel invasion assay for 3T3 cell lines transfected with either phrGFP control vector or with MUC16 carboxy-terminal constructs. Each assay was performed two or more times in triplicate and counted by hand. MUC16<sup>c80</sup> transfectant was significant (# p = 0.0172) compared to the MUC16<sup>c114</sup> cell line. C) Effect of MUC16 expression on ERK/AKT signaling. Transfected 3T3 cells were examined for activation of the ERK/AKT signaling pathways. Phosphorylation of ERK1/2 (pT202/Y204) and AKT (S473) was increased following MUC16<sup>c114</sup> transfection; however, the signals were lower with either the MUC16<sup>c80</sup> or MUC16<sup>c86</sup> constructs. Ī²-Actin normalized densitometry quantification values are shown below each Western blot. D) MUC16-positive tumor growth in athymic nude mice. Two million tumor cells were introduced into the flank of 20 nu/nu mice, and the mice were observed for tumor formation. Tumors were measured by calipers twice weekly. The differences in mean tumor volume were significantly greater for mice bearing MUC16 ectodomain positive tumors. 3T3 MUC16<sup>c114</sup> and 3T3 MUC16<sup>c86</sup> transfectants were significantly different compared to MUC16<sup>c80</sup> (### p<0.0001) and vector only animals.</p

    Effect of MUC16 in 3T3 cells.

    No full text
    <p>A) Soft agar growth of 3T3 transfectants in 60 mm dishes. After 14 days, colonies were counted and plotted. The data shown in the table represent one of three similar experiments (*** p < 0.0001) compared to the phrGFP control vector; B) Matrigel invasion assay for 3T3 cell lines following stable transfections with either the phrGFP control vector, MUC16<sup>c114</sup>-phrGFP or MUC16<sup>c344</sup> phrGFP carboxy-terminal constructs. Each assay was performed two or more times in triplicate and counted by hand. Both MUC16<sup>c114</sup> 3T3 and MUC16<sup>c344</sup> 3T3 cell lines were significantly more invasive (*** p<0.0001) compared to the phrGFP 3T3 vector control, and the MUC16<sup>c344</sup> cell line is significantly more invasive than the MUC16<sup>c114</sup> cell line (# p = 0.0354). C) Expression of metastasis and invasion genes induced by MUC16<sup>c114</sup> and MUC16<sup>c344</sup> expression. A SuperArray panel of 80 invasion/metastasis gene transcripts was examined for MUC16-positive and vector only cell lines. The expression of selected chemotactic, adhesion, and invasion transcripts was measured in 3T3 MUC16<sup>c114</sup> or 3T3-MUC16<sup>c344</sup> cell lines (each of three triplicates was examined in duplicate and compared to the phr vector only controls by chi square testing). The p value for each transcript, adjusted for repeated measures, is shown in the table. All genes with changes at the corrected p<0.05 or below level are included. D) Transfected 3T3 cells were examined for activation of the ERK/AKT signaling pathways compared to the vector only controls. Phosphorylation of ERK1/2 (pT202/Y204) and AKT (S473) was increased following MUC16<sup>c114</sup> and MUC16<sup>c344</sup> constructs, compared to the phrGFP vector. Activation of both pathways was seen in each of the cell lines. Ī²-Actin normalized densitometry quantification values are shown below each Western blot band. E) MUC16 transfectant tumor growth in athymic nude mice. Two million tumor cells were introduced into the flank of 15 nu/nu mice, and the mice were observed for tumor formation. Tumors were measured by calipers twice weekly. The differences in mean tumor volume were significantly greater for mice bearing MUC16-positive tumors (both lines p<0.0001 compared to the phrGFP control vector).</p
    corecore